[1] Toutounchi M, Shahhosseini M, Moumeni Moghadam M, Baharvand H. Epigenetic of stem cells. Yakhteh. 2008; 9(1): 51–66.

[2] Tronick E, Hunter RG. Waddington, dynamic systems, epigenetics. Frontiers in Behavioral Neuroscience. 2016; 10:107.

[3] Ghaedi K, Miri M, Tavassoli M. Process of epigenetic in cancer. Genetic in 3rd Millennium. 2007; 5(4): 1191-1195.

[4] Bird A. Perceptions of epigenetics. Nature. 2007; 447(7143): 396-8

[5] Feinberg AP, Tycko B. The history of cancer epigenetics. Nature Reviews Cancer. 2004; 4(2): 143-53.

[6] Hinshelwood RA, Clark SJ. Breast cancer epigenetics: normal human mammary epithelial cells as a model system. Journal of Molecular Medicine. 2008; 86(12): 1315-28.

[7] Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nature Reviews Genetics. 2007; 8(4): 286-98.

[8] Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007; 128(4): 683-92.

[9] Pfeifer GP, Besaratinia A. Mutational spectra of human cancer. Human Genetics. 2009; 125(5-6): 493-506.

[10] Bird A. DNA methylation patterns and epigenetic memory. Genes and Development. 2002; 16(1): 6-21.

[11] Stearns V, Zhou Q, Davidson NE. Epigenetic regulation as a new target for breast cancer therapy. Cancer Investigation. 2007; 25(8): 659-65.

[12] Abbasi B, Ansari Nejad N, Fardad F, Nasiripour S, Ramim T. Breast cancer epigenetics: review article. Tehran University Medical Journal TUMS Publications. 2016; 74(8): 535-44.

[13] Frigola J, Song J, Stirzaker C, Hinshelwood RA, Peinado MA, Clark SJ. Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nature Genetics. 2006; 38(5): 540-9.

[14] Byun DS, Lee MG, Chae KS, Ryu BG, Chi SG. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma. Cancer Research. 2001; 61(19): 7034-8.

[15] Nojima M, Suzuki H, Toyota M, Watanabe Y, Maruyama R, Sasaki S, et al. Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer. Oncogene. 2007; 26(32): 4699-713.

[16] Zeng XQ, Wang J, Chen SY. Methylation modification in gastric cancer and approaches to targeted epigenetic therapy. International Journal of Oncology. 2017; 50(6): 1921-33.

[17] Choi SJ, Jung SW, Huh S, Chung YS, Cho H, Kang H. Alteration of DNA Methylation in Gastric Cancer with Chemotherapy. Journal of Microbiology and Biotechnology. 2017; 27(8): 1367-78.

[18] Bernstein BE, Meissner A, Lander ES. The mammalian epigenome. Cell. 2007; 128(4): 669-81.

[19] Lande-Diner L, Cedar H. Silence of the genes—mechanisms of long-term repression. Nature Reviews Genetics. 2005; 6(8): 648-54.

[20] Lorincz MC, Dickerson DR, Schmitt M, Groudine M. Intragenic DNA methylation alters chromatin structure and elongation efficiency in mammalian cells. Nature Structural and Molecular Biology. 2004; 11(11): 1068-75.

[21] khalaj M, Abarzegar, MA Ebrahimzadeh, A farhadi. Study of the association of cyp3A4 gene promoter methylation with breast cancer incidence in Mazandaran province. The Conference of Novel Findings in Bioscience. 2017.

[22] Dehdari H, A barzegar, F moradian, MA Ebrahimzadeh. Methylation profile of the 5’ regulatory region of cyp1A1 gene in breast cancer patients. 3rd National Conference of New Cellular and Molecular,Ardebil. 2017.

[23] Esteller M. Epigenetics in cancer. New England Journal of Medicine. 2008; 358(11):
1148-59.

[24] Tahara E. Molecular mechanism of stomach carcinogenesis. Journal of Cancer Research and Clinical Oncology. 1993; 119(5): 265-72.

[25] Delgado S, Gómez M, Bird A, Antequera F. Initiation of DNA replication at CpG islands in mammalian chromosomes. The EMBO Journal. 1998; 17(8): 2426-35.

[26] Shim YH, Kang GH, Ro JY. Correlation of p16 hypermethylation with p16 protein loss in sporadic gastric carcinomas. Laboratory Investigation. 2000; 80(5): 689-95.

[27] Leung SY, Yuen ST, Chung LP, Chu KM, Chan AS, Ho JC. hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability. Cancer Research. 1999; 59(1): 159-64.

[28] Kang SH, Choi HH, Kim SG, Jong HS, Kim NK, Kim SJ, et al. Transcriptional inactivation of the tissue inhibitor of metalloproteinase−3 gene by dna hypermethylation of the 5’−CpG island in human gastric cancer cell lines. International Journal of Cancer. 2000; 86(5): 632-5.

[29] Bevilacqua RA, Simpson AJ. Methylation of the hMLH1 promoter but no hMLH1 mutations in sporadic gastric carcinomas with high−level microsatellite instability. International Journal of Cancer. 2000; 87(2): 200-3.

[30] Lee YY, Kang SH, Seo JY, Jung CW, Lee KU, Choe KJ, et al. Alterations of p16INK4A and p15INK4B genes in gastric carcinomas. Cancer. 1997; 80(10): 1889-96.

[31] Kissil JL, Feinstein E, Cohen O, Jones PA, Tsai YC, Knowles MA, et al. DAP-kinase loss of expression in various carcinoma and B-cell lymphoma cell lines: possible implications for role as tumor suppressor gene. Oncogene. 1997; 15(4): 403-7.

[32] Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Research. 1999; 59(1):67-70.

[33] Katzenellenbogen RA, Baylin SB, Herman JG. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood. 1999; 93(12): 4347- 53.

[34] Roberts DD. Regulation of tumor growth and metastasis by thrombospondin-1. The FASEB Journal. 1996; 10(10): 1183-91.

[35] Li Q, Ahuja N, Burger PC, Issa J-PJ. Methylation and silencing of the Thrombospondin-1 promoter in human cancer. Oncogene. 1999; 18(21): 3284-9.

[36] Yang N, Zhang L, Zhang Y, Kazazian Jr HH. An important role for RUNX3 in human L1 transcription and retrotransposition. Nucleic Acids Research. 2003; 31(16): 4929-40.

[37] Kouraklis G, Theocharis S. Histone deacetylase inhibitors and anticancer therapy. Current Medicinal Chemistry-Anti-Cancer Agents. 2002; 2(4): 477-84.

[38] Schübeler D, MacAlpine DM, Scalzo D, Wirbelauer C, Kooperberg C, Van Leeuwen F, et al. The histone modification pattern of active genes revealed through genomewide chromatin analysis of a higher eukaryote. Genes & Development. 2004; 18(11): 1263-71.

[39] Xu D, Bai J, Duan Q, Costa M, Dai W. Covalent modifications of histones during mitosis and meiosis. Cell Cycle. 2009; 8(22): 3688-94.

[40] Mellor J. The dynamics of chromatin remodeling at promoters. Molecular Cell. 2005; 19(2): 147-57.

[41] Altieri F, Di Stadio CS, Federico A, Miselli G, De Palma M, Rippa E, et al. Epigenetic alterations of gastrokine 1 gene expression in gastric cancer. Oncotarget. 2017; 8(10): 16899.

[42] Nan X, Ng H-H, Johnson CA, Laherty CD, Turner BM, Eisenman RN, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature. 1998; 393(6683): 386-9.

[43] Robertson KD, Ait-Si-Ali S, Yokochi T, Wade PA, Jones PL, Wolffe AP. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nature Genetics. 2000; 25(3): 338-42.

[44] Bachman KE, Rountree MR, Baylin SB. Dnmt3a and Dnmt3b are transcriptional repressors that exhibit unique localization properties to heterochromatin. Journal of Biological Chemistry. 2001; 276(34): 32282-7.

[45] Rose NR, Klose RJ. Understanding the relationship between DNA methylation and histone lysine methylation. Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms. 2014; 1839(12): 1362-72.

[46] Rea S, Eisenhaber F, O’carroll D, Strahl BD, Sun Z-W, Schmid M, et al. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature. 2000; 406(6796): 593-9.

[47] De Murcia G, Shall S. From DNA damage and stress signalling to cell death: poly ADP-ribosylation reactions: Oxford University Press on Demand; 2000.

[48] Zardo G, Reale A, Matteis GD, Buontempo S, Caiafa P. A role for poly (ADP-ribosyl) ation in DNA methylation. Biochemistry and Cell Biology. 2003; 81(3): 197-208.

[49] Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nature Genetics. 2005; 37(4): 391-400.

[50] Seligson DB, Horvath S, Shi T, Yu H. Global histone modification patterns predict risk of prostate cancer recurrence. Nature. 2005; 435(7046): 1262.

[51] Allfrey V, Faulkner R, Mirsky A. Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proceedings of the National Academy of Sciences. 1964; 51(5): 786-94.

[52] Zhou S TA, Lupien M. Emergence of the noncoding cancer genome: a target of genetic and epigenetic alterations. Cancer Discovery. 2016 Nov; 6(11): 1215-29.

[53] Forsberg EC, Bresnick EH. Histone acetylation beyond promoters: long−range acetylation patterns in the chromatin world. Bioessays. 2001; 23(9): 820-30.

[54] Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nature Reviews Drug Discovery. 2002; 1(4): 287-99.

[55] Fraga MF BE, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K, Iyer NG. Histone deacetylases and cancer: causes and therapies. Nature Reviews Cancer. 2001; 1(3): 194-202.

[56] Timmermann S, Lehrmann H, Polesskaya A, Harel-Bellan A. Histone acetylation and disease. Cellular and Molecular Life Sciences. 2001; 58(5): 728-36.

[57] Grunstein M. Histone acetylation in chromatin structure and transcription. Nature. 1997; 389(6649): 349.

[58] Wang GG, Allis CD, Chi P. Chromatin remodeling and cancer, Part I: Covalent histone modifications. Trends in Molecular Medicine. 2007; 13(9): 363-72.

[59] Inche AG, La Thangue NB. Keynote review: Chromatin control and cancer-drug discovery: realizing the promise. Drug Discovery Today. 2006; 11(3): 97-109.

[60] Yasui W, Oue N, Ono S, Mitani Y, Ito R, Nakayama H. Histone acetylation and gastrointestinal carcinogenesis. Annals of the New York Academy of Sciences. 2003; 983(1): 220-31.

[61] Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of nonhistone proteins. Gene. 2005; 363: 15-23.

[62] Davis PK, Brachmann RK. Chromatin remodeling and cancer. Cancer Biology and Therapy. 2003; 2(1): 23-30.

[63] Gayther SA, Batley SJ, Linger L, Bannister A, Thorpe K, Chin S-F, et al. Mutations truncating the EP300 acetylase in human cancers. Nature Genetics. 2000; 24(3): 300.

[64] Gorrini C, Squatrito M, Luise C, Syed N, Perna D, Wark L, et al. Tip60 is a haploinsufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature. 2007; 448(7157): 1063.

[65] Sykes SM, Mellert HS, Holbert MA, Li K, Marmorstein R, Lane WS, et al. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Molecular Cell. 2006; 24(6): 841-51.

[66] Avvakumov N, Cote J. The MYST family of histone acetyltransferases and their intimate links to cancer. Oncogene. 2007; 26(37): 5395.

[67] Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nature Reviews Drug Discovery. 2006; 5(9): 769.

[68] Glozak M, Seto E. Histone deacetylases and cancer. Oncogene. 2007;26(37):5420.

[69] Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: What are the cancer relevant targets?. Cancer Letters. 2009; 277(1): 8-21.

[70] Inoue S, Mai A, Dyer MJ, Cohen GM. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor– related apoptosis-inducing ligand–induced apoptosis. Cancer Research. 2006; 66(13): 6785-92.

[71] Wilson AJ, Byun D-S, Popova N, Murray LB, L’Italien K, Sowa Y, et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. Journal of Biological Chemistry. 2006; 281(19): 13548-58.

[72] Nakagawa M, Oda Y, Eguchi T, Aishima S-I, Yao T, Hosoi F, et al. Expression profile of class I histone deacetylases in human cancer tissues. Oncology Reports. 2007;18(4):769-74.

[73] Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101(2): 540-5.

[74] Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(10): 3697-702.

[75] Haggarty SJ KK, Wong JC, Grozinger CM, Schreiber SL. Domain-selective smallmolecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proceedings of the National Academy of Sciences. 2003; 100(8): 4389-94.

[76] Wilson AJ, Byun D-S, Nasser S, Murray LB, Ayyanar K, Arango D, et al. HDAC4 promotes growth of colon cancer cells via repression of p21. Molecular Biology of the Cell. 2008; 19(10): 4062-75.

[77] Mottet D, Bellahcène A, Pirotte S, Waltregny D, Deroanne C, Lamour V, et al. Histone deacetylase 7 silencing alters endothelial cell migration, a key step in angiogenesis. Circulation Research. 2007; 101(12): 1237-46.

[78] Park JH, Kim SH, Choi MC, Lee J, Oh DY, Im SA, et al. Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors. Biochemical and Biophysical Research Communications. 2008; 368(2): 318-22.

[79] Wang S, Cheng Y, Du W, Lu L, Zhou L, Wang H, et al. Zinc-finger protein 545 is a novel tumour suppressor that acts by inhibiting ribosomal RNA transcription in gastric cancer. Gut. 2013; 62(6): 833-841

[80] Wang X, Lau KK, So LK, Lam YW. CHD5 is down-regulated through promoter hypermethylation in gastric cancer. Journal of Biomedical Science. 2009; 16(1): 95.

[81] Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, Joo HJ, et al. Expression profile of histone deacetylase 1 in gastric cancer tissues. Cancer Science. 2001; 92(12): 1300-4.

[82] Halkidou K, Gaughan L, Cook S, Leung HY, Neal DE, Robson CN. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. The Prostate.2004; 59(2): 177-89.

[83] Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, et al. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast Cancer Research and Treatment. 2005;94(1): 11-6.

[84] Zhu P, Martin E, Mengwasser J, Schlag P, Janssen K-P, Göttlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell. 2004; 5(5): 455-63.

[85] Song J, Noh JH, Lee JH, Eun JW, Ahn YM, Kim SY, et al. Increased expression of histone deacetylase 2 is found in human gastric cancer. Apmis. 2005; 113(4): 264-8.

[86] Zhang Z, Yamashita H, Toyama T, Sugiura H, Omoto Y, Ando Y, et al. HDAC6 expression is correlated with better survival in breast cancer. Clinical Cancer Research. 2004; 10(20): 6962-8.

[87] Satoh A, Toyota M, Itoh F, Kikuchi T, Obata T, Sasaki Y, et al. DNA methylation and histone deacetylation associated with silencing DAP kinase gene expression in colorectal and gastric cancers. British Journal of Cancer. 2002; 86(11): 1817-23.

[88] Black JC, Van Rechem C, Whetstine JR. Histone lysine methylation dynamics: establishment, regulation, and biological impact. Molecular Cell. 2012;48(4):491-507.

[89] Yokoyama A, Wang Z, Wysocka J, Sanyal M, Aufiero DJ, Kitabayashi I, et al. Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Molecular and Cellular Biology. 2004; 24(13): 5639-49.

[90] Cao R, Zhang Y. The functions of E (Z)/EZH2-mediated methylation of lysine 27 in histone H3. Current Opinion in Genetics and Development. 2004; 14(2): 155-64.

[91] Wysocka J, Swigut T, Xiao H, Milne TA, Kwon SY, Landry J, et al. A PHD finger of NURF couples histone H3 lysine 4 trimethylation with chromatin remodelling. Nature. 2006; 442(7098): 86.

[92] Francis NJ, Kingston RE, Woodcock CL. Chromatin compaction by a polycomb group protein complex. Science. 2004; 306(5701): 1574-7.

[93] Akiyama Y, Maesawa C, Ogasawara S, Terashima M, Masuda T. Cell-type-specific repression of the maspin gene is disrupted frequently by demethylation at the promoter region in gastric intestinal metaplasia and cancer cells. The American Journal of Pathology. 2003; 163(5): 1911-9.

[94] Kaustov L, Ouyang H, Amaya M, Lemak A, Nady N, Duan S, et al. Recognition and specificity determinants of the human cbx chromodomains. Journal of Biological Chemistry. 2011; 286(1): 521-9.

[95] Di Lorenzo A, Bedford MT. Histone arginine methylation. FEBS Letters. 2011; 585(13):2024-31.

[96] Hyllus D, Stein C, Schnabel K, Schiltz E, Imhof A, Dou Y, et al. PRMT6-mediated methylation of R2 in histone H3 antagonizes H3 K4 trimethylation. Genes & Development. 2007; 21(24): 3369-80.

[97] Migliori V, Müller J, Phalke S, Low D, Bezzi M, Mok WC, et al. Symmetric dimethylation of H3R2 is a newly identified histone mark that supports euchromatin maintenance. Nature Structural and Molecular Biology. 2012; 19(2): 136-44.

[98] Liu K, Guo Y, Liu H, Bian C, Lam R, Liu Y, et al. Crystal structure of TDRD3 and methylarginine binding characterization of TDRD3, SMN and SPF30. PloS One. 2012; 7(2): e30375.

[99] Xhemalce B DM, Bannister AJ. Histone modifications. Reviews in Cell Biology and Molecular Medicine. 2011.

[100] Kouzarides T BS. Chromatin modifications and their mechanism of action. Epigenetics. 2007; 191: 209.

[101] Takahashi H MY, Tsuneyama K, Nomoto K, Okada E, Fujita H, Takano Y. Over expression of phosphorylated histone H3 is an indicator of poor prognosis in gastric adenocarcinoma patients. Applied Immunohistochemistry & Molecular Morphology. 2006; 14(3): 296-302.

[102] Oki M AH, Ito T Role of histone phosphorylation in chromatin dynamics and its implications in diseases. Chromatin and Disease. 2007: 323-40.

[103] Hu S XZ, Onishi A, Yu X, Jiang L, Lin J, Rho HS, Woodard C, Wang H, Jeong JS, Long S. Profiling the human protein-DNA interactome reveals ERK2 as a transcriptional repressor of interferon signaling. Cell. 2009; 139(3): 310-622.

[104] Henry KW WA, Lo WS, Duggan LJ, Emre NT, Kao CF, Pillus L, Shilatifard A, Osley MA, Berger SL. . Transcriptional activation via sequential histone H2B ubiquitylation and deubiquitylation, mediated by SAGA-associated Ubp8. Genes and Development. 2003; 17(21): 2648-63.

[105] Shiio Y ER. Histone sumoylation is associated with transcriptional repression. Proceedings of the National Academy of Sciences. 2003; 100(23): 13225-30.

[106] Cheng Y, Jin H, Liu X, Siu J, Wong Y, Ng E, et al. Fibulin 1 is downregulated through promoter hypermethylation in gastric cancer. British Journal of Cancer. 2008; 99(12): 2083.

[107] Shin CM, Kim N, Jung Y, Park JH, Kang GH, Park WY, et al. Genome−Wide DNA Methylation Profiles in Noncancerous Gastric Mucosae with Regard to Helicobacterpylori Infection and the Presence of Gastric Cancer. Helicobacter. 2011; 16(3): 179-88.

[108] Murai M, Toyota M, Suzuki H, Satoh A, Sasaki Y, Akino K, et al. Aberrant methylation and silencing of the BNIP3 gene in colorectal and gastric cancer. Clinical Cancer Research. 2005; 11(3): 1021-7.

[109] Mikata R, Fukai K, Imazeki F, Arai M, Fujiwara K, Yonemitsu Y, et al. BCL2L10 is frequently silenced by promoter hypermethylation in gastric cancer. Oncology Reports. 2010; 23(6): 1701-8.

[110] Xu JD, Cao XX, Long ZW, Liu XP, Furuya T, Xu JW, et al. BCL2L10 protein regulates apoptosis/proliferation through differential pathways in gastric cancer cells. The Journal of Pathology. 2011; 223(3): 400-9.

[111] Li X, Cheung K, Ma X, Tian L, Zhao J, Go M, et al. Epigenetic inactivation of paired box gene 5, a novel tumor suppressor gene, through direct upregulation of p53 is associated with prognosis in gastric cancer patients. Oncogene. 2012; 31(29): 3419.

[112] Dong W, Feng L, Xie Y, Zhang H, Wu Y. Hypermethylation−mediated reduction of LMX1A expression in gastric cancer. Cancer Science. 2011; 102(2): 361-6.

[113] Akiyama Y, Watkins N, Suzuki H, Jair K-W, van Engeland M, Esteller M, et al. GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Molecular and Cellular Biology. 2003; 23(23): 8429-39.

[114] Balgkouranidou I, Karayiannakis A, Matthaios D, Bolanaki H, Tripsianis G, Tentes AA, et al. Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival. Clinical Chemistry and Laboratory Medicine. 2013; 51(7): 1505-10.

[115] Bian Y, Wang L, Lu H, Yang G, Zhang Z, Fu H, et al. Downregulation of tumor suppressor QKI in gastric cancer and its implication in cancer prognosis. Biochemical and Biophysical Research Communications. 2012; 422(1): 187-93.

[116] Guo X, Jing C, Li L, Zhang L, Shi Y, Wang J, et al. Down-regulation of VEZT gene expression in human gastric cancer involves promoter methylation and miR-43c. Biochemical and Biophysical Research Communications. 2011; 404(2): 622-7.

[117] Dohi O, Takada H, Wakabayashi N, Yasui K, Sakakura C, Mitsufuji S, et al. Epigenetic silencing of RELN in gastric cancer. International Journal of Oncology. 2010;36(1):85- 92.

[118] Guan Z, Zhang J, Song S, Dai D. Promoter methylation and expression of TIMP3 gene in gastric cancer. Diagnostic Pathology. 2013; 8(1): 110.

[119] Du W, Wang S, Zhou Q, Li X, Chu J, Chang Z, et al. ADAMTS9 is a functional tumor suppressor through inhibiting AKT/mTOR pathway and associated with poor survival in gastric cancer. Oncogene. 2013; 32(28): 3319-28.

[120] Piazzi G, Fini L, Selgrad M, Garcia M, Daoud Y, Wex T, et al. Epigenetic regulation of Delta-Like1 controls Notch1 activation in gastric cancer. Oncotarget. 2011; 2(12): 1291.

[121] Mikata R, Yokosuka O, Fukai K, Imazeki F, Arai M, Tada M, et al. Analysis of genes upregulated by the demethylating agent 5−aza−2′−deoxycytidine in gastric cancer cell lines. International Journal of Cancer. 2006; 119(7): 1616-22.

[122] Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H, Hinoda Y, et al. Distinct methylation pattern and microsatellite instability in sporadic gastric cancer. International Journal of Cancer. 1999; 83(3): 309-13.

[123] Zhi Y, Chen J, Zhang S, Chang X, Ma J, Dai D. Down-regulation of CXCL12 by DNA hypermethylation and its involvement in gastric cancer metastatic progression. Digestive Diseases and Sciences. 2012; 57(3): 650-9.

[124] Leung WK, To KF, Chu ES, Chan MW, Bai AH, Ng EK, Chan FK, Sung JJ. Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer. British Journal of Cancer. 2005; 92(12): 2190.

[125] Tahara T, Shibata T, Nakamura M, Yamashita H, Yoshioka D, Okubo M, et al. Increased number of CpG island hypermethylation in tumor suppressor genes of non-neoplastic gastric mucosa correlates with higher risk of gastric cancer. Digestion. 2010; 82(1): 27-36.

[126] Kang GH, Lee S, Cho N-Y, Gandamihardja T, Long TI, Weisenberger DJ, et al. DNA methylation profiles of gastric carcinoma characterized by quantitative DNA methylation analysis. Laboratory investigation. 2008; 88(2): 161.

[127] Dote H, Toyooka S, Tsukuda K, Yano M, Ota T, Murakami M, et al. Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in gastrointestinal tumour. British Journal of Cancer. 2005; 92(6): 1117.

[128] Yao D, Shi J, Shi B, Wang N, Liu W, Zhang G, et al. Quantitative assessment of gene methylation and their impact on clinical outcome in gastric cancer. Clinica Chimica Acta. 2012; 413(7): 787-94.

[129] Agathanggelou A, Cooper WN, Latif F. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Research. 2005; 65(9): 3497-508.

[130] Ksiaa F, Ziadi S, Amara K, Korbi S, Trimeche M. Biological significance of promoter hypermethylation of tumor-related genes in patients with gastric carcinoma. Clinica Chimica Acta. 2009; 404(2): 128-33.

[131] Guo W, Dong Z, Guo Y, Lin X, Chen Z, Kuang G, et al. Aberrant methylation and loss expression of RKIP is associated with tumor progression and poor prognosis in gastric cardia adenocarcinoma. Clinical & Experimental Metastasis. 2013; 30(3): 265-75.

[132] To K, Chan M, Leung W, Ng E, Yu J, Bai A, et al. Constitutional activation of IL-6- mediated JAK/STAT pathway through hypermethylation of SOCS-1 in human gastric cancer cell line. British Journal of Cancer. 2004; 91(7):1335.

[133] Souma Y, Nishida T, Serada S, Iwahori K, Takahashi T, Fujimoto M, et al. Antiproliferative effect of SOCS−1 through the suppression of STAT3 and p38 MAPK activation in gastric cancer cells. International Journal of Cancer. 2012;131(6):1287-96.

[134] Radulescu S, Ridgway R, Cordero J, Athineos D, Salgueiro P, Poulsom R, et al. Acute WNT signalling activation perturbs differentiation within the adult stomach and rapidly leads to tumour formation. Oncogene. 2013; 32(16): 2048.

[135] Deng G, Song G-A, Pong E, Sleisenger M, Kim YS. Promoter methylation inhibits APC gene expression by causing changes in chromatin conformation and interfering with the binding of transcription factor CCAAT-binding factor. Cancer Research. 2004; 64(8): 2692-8.

[136] Yu J, Tao Q, Cheng YY, Lee KY, Ng SS, Cheung KF, et al. Promoter methylation of the Wnt/β−catenin signaling antagonist Dkk−3 is associated with poor survival in gastric cancer. Cancer. 2009; 115(1): 49-60.

[137] Guo Y, Guo W, Chen Z, Kuang G, Yang Z, Dong Z. Hypermethylation and aberrant expression of Wnt-antagonist family genes in gastric cardia adenocarcinoma. Neoplasma. 2011; 58(2): 110-7.

[138] Kobayashi K, Ouchida M, Tsuji T, Hanafusa H, Miyazaki M, Namba M, et al. Reduced expression of the REIC/Dkk-3 gene by promoter-hypermethylation in human tumor cells. Gene. 2002; 282(1): 151-8.

[139] Shutoh M, Oue N, Aung PP, Noguchi T, Kuraoka K, Nakayama H, et al. DNA methylation of genes linked with retinoid signaling in gastric carcinoma. Cancer. 2005; 104(8): 1609-19.

[140] Jeronimo C, Henrique R, Oliveira J, Lobo F, Pais I, Teixeira M, et al. Aberrant cellular retinol binding protein 1 (CRBP1) gene expression and promoter methylation in prostate cancer. Journal of Clinical Pathology. 2004; 57(8): 872-6.

[141] Narayan G, Arias-Pulido H, Koul S, Vargas H, Zhang FF, Villella J, et al. Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Molecular Cancer. 2003; 2(1): 24.

[142] Ben Ayed−Guerfali D, Benhaj K, Khabir A, Abid M, Bayrouti MI, Sellami−Boudawara T, et al. Hypermethylation of tumor−related genes in tunisian patients with gastric carcinoma: Clinical and biological significance. Journal of Surgical Oncology. 2011; 103(7): 687-94.

[143] Oue N, Mitani Y, Motoshita J, Matsumura S, Yoshida K, Kuniyasu H, et al. Accumulation of DNA methylation is associated with tumor stage in gastric cancer. Cancer. 2006; 106(6): 1250-9.

[144] Yamashita S, Tsujino Y, Moriguchi K, Tatematsu M, Ushijima T. Chemical genomic screening for methylation−silenced genes in gastric cancer cell lines using 5−aza−2′−deoxycytidine treatment and oligonucleotide microarray. Cancer Science. 2006; 97(1): 64-71.

[145] Hiraki M, Kitajima Y, Koga Y, Tanaka T, Nakamura J, Hashiguchi K, et al. Aberrant gene methylation is a biomarker for the detection of cancer cells in peritoneal wash samples from advanced gastric cancer patients. Annals of Surgical Oncology. 2011; 18(10): 3013-9.

[146] Sugita H, Iida S, Inokuchi M, Kato K, Ishiguro M, Ishikawa T, et al. Methylation of BNIP3 and DAPK indicates lower response to chemotherapy and poor prognosis in gastric cancer. Oncology Reports. 2011; 25(2): 513-8.

[147] Shi J, Zhang G, Yao D, Liu W, Wang N, Ji M, et al. Prognostic significance of aberrant gene methylation in gastric cancer. American Journal of Cancer Research. 2012; 2(1):116.

[148] Joo JK, Kim SH, Kim HG, Kim DY, Ryu SY, Lee KH, et al. CpG methylation of transcription factor 4 in gastric carcinoma. Annals of Surgical Oncology. 2010; 17(12): 3344-53.

[149] Shu X-s, Geng H, Li L, Ying J, Ma C, Wang Y, et al. The epigenetic modifier PRDM5 functions as a tumor suppressor through modulating WNT/β-catenin signaling and is frequently silenced in multiple tumors. PloS One. 2011; 6(11): e27346.

[150] Wang L, Chen S, Xue M, Zhong J, Wang X, Gan L, et al. Homeobox D10 gene, a candidate tumor suppressor, is downregulated through promoter hypermethylation and associated with gastric carcinogenesis. Molecular Medicine. 2012; 18(1): 389.

[151] Chang X, Li Z, Ma J, Deng P, Zhang S, Zhi Y, et al. DNA methylation of NDRG2 in gastric cancer and its clinical significance. Digestive Diseases and Sciences. 2013; 58(3): 715-23.

[152] Wang Y, Li J, Cui Y, Li T, Ng KM, Geng H, et al. CMTM3, located at the critical tumor Suppressor locus 16q22. 1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis. Cancer Research. 2009; 69(12): 5194- 201.

[153] Yu J, Cheng YY, Tao Q, Cheung KF, Lam CN, Geng H, et al. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology. 2009; 136(2): 640-51.

[154] Cheng Y, Yu J, Wong Y, Man E, To K, Jin V, et al. Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer. British Journal of Cancer. 2007; 97(7): 895.

[155] Do Jee C, Kim MA, Jung EJ, Kim J, Kim WH. Identification of genes epigenetically silenced by CpG methylation in human gastric carcinoma. European Journal of Cancer. 2009; 45(7): 1282-93.

[156] Peng D-F, Hu T-L, Schneider BG, Chen Z, Xu Z-K, El-Rifai W. Silencing of glutathione peroxidase 3 through DNA hypermethylation is associated with lymph node metastasis in gastric carcinomas. PLoS One. 2012; 7(10): e46214.

[157] Tamura G, Yin J, Wang S, Fleisher AS, Zou T, Abraham JM, et al. E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. JNCI: Journal of the National Cancer Institute. 2000; 92(7): 569-73.

[158] Guo W, Dong Z, Guo Y, Chen Z, Kuang G, Yang Z. Aberrant methylation of the CpG island of HLTF gene in gastric cardia adenocarcinoma and dysplasia. Clinical Biochemistry. 2011; 44(10): 784-8.

[159] Wani M, Afroze D, Makhdoomi M, Hamid I, Wani B, Bhat G, et al. Promoter methylation status of DNA repair gene (hMLH1) in gastric carcinoma patients of the Kashmir valley. Asian Pacific Journal of Cancer Prevention. 2012; 13(8): 4177-81.

[160] Ling Z-Q, Tanaka A, Li P, Nakayama T, Fujiyama Y, Hattori T, et al. Microsatellite instability with promoter methylation and silencing of hMLH1 can regionally occur during progression of gastric carcinoma. Cancer Letters. 2010; 297(2): 244-51.

[161] Hibi K, Sakata M, Yokomizo K, Kitamura Y-H, Sakuraba K, Shirahata A, et al. Methylation of the MGMT gene is frequently detected in advanced gastric carcinoma. Anticancer Research. 2009; 29(12): 5053-5.

[162] Schneider BG, Peng DF, Camargo MC, Piazuelo MB, Sicinschi LA, Mera R, et al. Promoter DNA hypermethylation in gastric biopsies from subjects at high and low risk for gastric cancer. International Journal of Cancer. 2010; 127(11): 2588-97.

[163] Wu CS, Lu YJ, Li HP, Hsueh C, Lu CY, Leu YW, et al. Glutamate receptor, ionotropic, kainate 2 silencing by DNA hypermethylation possesses tumor suppressor function in gastric cancer. International Journal of Cancer. 2010; 126(11): 2542-52.

[164] Kaneda A, Wakazono K, Tsukamoto T, Watanabe N, Yagi Y, Tatematsu M, et al. Lysyl oxidase is a tumor suppressor gene inactivated by methylation and loss of heterozygosity in human gastric cancers. Cancer research. 2004; 64(18): 6410-5.

[165] Guo W, Dong Z, He M, Guo Y, Guo J, Chen Z, Yang Z, Kuang G. Aberrant methylation of thrombospondin-1 and its association with reduced expression in gastric cardia adenocarcinoma. BioMed Research International. 2010 Mar 15.

[166] Xiong H-L, Liu X-Q, Sun A-H, He Y, Li J, Xia Y. Aberrant DNA methylation of P16, MGMT, hMLH1 and hMSH2 genes in combination with the MTHFR C677T genetic polymorphism in gastric cancer. Asian Pacific Journal of Cancer Prevention. 2013; 14(5): 3139-42.

[167] Kim Y-K, Yu J, Han TS, Park S-Y, Namkoong B, Kim DH, et al. Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic Acids Research. 2009; 37(5): 1672-81.

[168] Yuasa Y, Nagasaki H, Akiyama Y, Hashimoto Y, Takizawa T, Kojima K, et al. DNA methylation status is inversely correlated with green tea intake and physical activity in gastric cancer patients. International Journal of Cancer. 2009; 124(11): 2677-82.

[169] Chen Q, Chen X, Zhang M, Fan Q, Luo S, Cao X. miR-137 is frequently down-regulated in gastric cancer and is a negative regulator of Cdc42. Digestive Diseases and Sciences. 2011; 56(7): 2009-16.

[170] Xu Y, Deng Y, Yan X, Zhou T. Targeting miR-375 in gastric cancer. Expert Opinion on Therapeutic Targets. 2011; 15(8): 961-72.

[171] Wei B, Song Y, Zhang Y, Hu M. microRNA-449a functions as a tumor-suppressor in Gastric adenocarcinoma by targeting Bcl-2. Oncology Letters. 2013; 6(6): 1713-8.

[172] Deng H, Guo Y, Song H, Xiao B, Sun W, Liu Z, et al. MicroRNA-195 and microRNA378 mediate tumor growth suppression by epigenetical regulation in gastric cancer. Gene. 2013; 518(2): 351-9.

[173] Kong WQ, Bai R, Liu T, Cai CL, Liu M, Li X, et al. MicroRNA−182 targets cAMP−responsive element−binding protein 1 and suppresses cell growth in human gastric adenocarcinoma. The FEBS Journal. 2012; 279(7): 1252-60.

[174] Xu L, Wang F, Xu X-F, Mo W-H, Xia Y-J, Wan R, et al. Down-regulation of miR212 expression by DNA hypermethylation in human gastric cancer cells. Medical Oncology. 2011;28(1):189-96.

[175] Liang S, He L, Zhao X, Miao Y, Gu Y, Guo C, et al. MicroRNA let-7f inhibits tumor invasion and metastasis by targeting MYH9 in human gastric cancer. PLoS One. 2011; 6(4): e18409.

[176] Li P, Chen X, Su L, Li C, Zhi Q, Yu B, et al. Epigenetic silencing of miR-338-3p contributes to tumorigenicity in gastric cancer by targeting SSX2IP. PLoS One. 2013; 8(6): e66782.

[177] Tsai K-W, Liao Y-L, Wu C-W, Hu L-Y, Li S-C, Chan W-C, et al. Aberrant hypermethylation of miR-9 genes in gastric cancer. Epigenetics. 2011; 6(10): 1189-97.

[178] Wu H, Huang M, Lu M, Zhu W, Shu Y, Cao P, et al. Regulation of microtubuleassociated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel. Cancer Chemotherapy and Pharmacology. 2013; 71(5):1159-71.

[179] Zhu W, Xu H, Zhu D, Zhi H, Wang T, Wang J, et al. miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemotherapy and Pharmacology. 2012; 69(3): 723-31.

[180] Kwon OH, Park JL, Baek SJ, Noh SM, Song KS, Kim SY, et al. Aberrant upregulation of ASCL2 by promoter demethylation promotes the growth and resistance to 5−fluorouracil of gastric cancer cells. Cancer Science. 2013; 104(3): 391-7.

[181] de Souza CRT, Leal MF, Calcagno DQ, Sozinho EKC, do Nascimento Borges B, Montenegro RC, et al. MYC deregulation in gastric cancer and its clinicopathological implications. PloS One. 2013; 8(5): e64420.

[182] Yashiro M, Yasuda K, Nishii T, Kaizaki R, Sawada T, Ohira M, et al. Epigenetic regulation of the embryonic oncogene ERas in gastric cancer cells. International Journal of Oncology. 2009; 35(5): 997-1003.

[183] Dong W, Wang L, Chen X, Sun P, Wu Y. Upregulation and CpG island hypomethylation of the TRF2 gene in human gastric cancer. Digestive Diseases and Sciences. 2010; 55(4): 997-1003.

[184] Balassiano K, Lima S, Jenab M, Overvad K, Tjonneland A, Boutron-Ruault MC, et al. Aberrant DNA methylation of cancer-associated genes in gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC–EURGAST). Cancer Letters. 2011; 311(1): 85-95.

[185] Niinuma T, Suzuki H, Nojima M, Nosho K, Yamamoto H, Takamaru H, Yamamoto E, Maruyama R, Nobuoka T, Miyazaki Y, Nishida T. Upregulation of miR-196a and HOTAIR drive malignant character in gastrointestinal stromal tumors. Cancer Research. 2012; 72(5): 1126-36.

[186] He L-J, Cai M-Y, Xu G-L, Li J-J, Weng Z-J, Xu D-Z, et al. Prognostic significance of overexpression of EZH2 and H3k27me3 proteins in gastric cancer. Asian Pacific Journal of Cancer Prevention. 2012; 13(7): 3173-8.

[187] Sakuraba K, Yokomizo K, Shirahata A, Goto T, Saito M, Ishibashi K, et al. TIP60 as a potential marker for the malignancy of gastric cancer. Anticancer Research. 2011;31(1):77-9.

[188] Qinyu L, Long C, Zhen-dong D, Min-min S, Wei-ze W, Wei-ping Y, et al. FOXO6 promotes gastric cancer cell tumorigenicity via upregulation of C−myc. FEBS letters. 2013; 587(14): 2105-11.

[189] Rotkrua P, Akiyama Y, Hashimoto Y, Otsubo T, Yuasa Y. MiR−9 downregulates CDX2 expression in gastric cancer cells. International Journal of Cancer. 2011;129(11):2611-20.

[190] Gigek CO, Lisboa LCF, Leal MF, Silva PNO, Lima EM, Khayat AS, et al. SMARCA5 methylation and expression in gastric cancer. Cancer Investigation. 2011; 29(2): 162- 6.

[191] Yang Q ZR, Sui PC, He HT, Ding L. . Dysregulation of non-coding RNAs in gastric cancer. World Journal of Gastroenterology. 2015; 21(39): 10956.

[192] Tang G, M. Tang, and Y. Xie, . J The role of miRNAs in gastric cancer. Gastroint Dig Syst. 2013; 3(129): 2069-161.

[193] Laird PW, Jackson-Grusby L, Fazeli A, Dickinson SL, Jung WE, Li E, et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell. 1995; 81(2): 197-205.

[194] Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell. 1980; 20(1): 85-93.

[195] Fandy TE, Herman JG, Kerns P, Jiemjit A, Sugar EA, Choi S-H, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood. 2009; 114(13): 2764-73.

[196] Rius M, Lyko F. Epigenetic cancer therapy: rationales, targets and drugs. Oncogene. 2012; 31(39): 4257-65.

[197] Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. Journal of Clinical oncology. 2002; 20(10): 2429-40.

[198] Kantarjian H, Issa JPJ, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes. Cancer. 2006; 106(8): 1794-803.

[199] Issa J-PJ, Kantarjian HM. Targeting DNA methylation. Clinical Cancer Research. 2009; 15(12): 3938-46.